Efficacy for Part 1: •Proportion of patient with negative conversion in nasopharyngeal swab specimen based on RT-qPCR or cell culture at each visit up to Day 14 OR •Time to negative conversion in nasopharyngeal swab specimen based on RT-qPCR or cell culture up to Day 14 OR •Time to clinical recovery up to Day 14 OR •Proportion of patients with experiencing clinical symptom requiring additional prescription medication, hospitalization, or oxygen therapy up to Day 28 Clinical recovery is defined as all symptoms on the SARS-CoV-2 Infection Symptom Checklist being recorded as ‘absent’ or ‘mild’ in intensity for at least 24 hours. To meet the clinical recovery, symptoms ‘moderate’ or ‘severe’ in intensity at baseline should be changed to ‘mild’ or ‘absent’, or symptoms ‘mild’ in intensity at baseline should be changed to ‘absent’, after the study drug administration. If a symptom ‘absent’ in intensity at baseline becomes ‘severe’, ‘moderate’, or ‘mild’ during the study, this should be changed back to ‘absent’ for at least 24 hours. Symptoms of SARS-CoV-2 Infection Symptom Checklist are defined as feeling feverish, cough, shortness of breath or difficulty breathing, sore throat, body pain or muscle pain, fatigue, and headache Efficacy for Part 2: The primary efficacy endpoint of Part 2 is a proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection up to Day 28

Efficacy for Part 1: •Proportion of patient with negative conversion in nasopharyngeal swab specimen based on RT-qPCR or cell culture at each visit up to Day 14 OR •Time to negative conversion in nasopharyngeal swab specimen based on RT-qPCR or cell culture up to Day 14 OR •Time to clinical recovery up to Day 14 OR •Proportion of patients with experiencing clinical symptom requiring additional prescription medication, hospitalization, or oxygen therapy up to Day 28 Clinical recovery is defined as all symptoms on the SARS-CoV-2 Infection Symptom Checklist being recorded as ‘absent’ or ‘mild’ in intensity for at least 24 hours. To meet the clinical recovery, symptoms ‘moderate’ or ‘severe’ in intensity at baseline should be changed to ‘mild’ or ‘absent’, or symptoms ‘mild’ in intensity at baseline should be changed to ‘absent’, after the study drug administration. If a symptom ‘absent’ in intensity at baseline becomes ‘severe’, ‘moderate’, or ‘mild’ during the study, this should be changed back to ‘absent’ for at least 24 hours. Symptoms of SARS-CoV-2 Infection Symptom Checklist are defined as feeling feverish, cough, shortness of breath or difficulty breathing, sore throat, body pain or muscle pain, fatigue, and headache Efficacy for Part 2: The primary efficacy endpoint of Part 2 is a proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection up to Day 28